A growth modulation index-based geistra score as a new prognostic tool for trabectedin efficacy in patients with advanced soft tissue sarcomas : A Spanish group for sarcoma research (GEIS) retrospective study
Martínez-Trufero, Javier (Hospital Universitario Miguel Servet (Saragossa))
Sande-González, Luis Miguel de (Hospital Universitario de León)
Luna, Pablo (Hospital Universitari Son Espases (Palma de Mallorca, Balears))
Martín-Broto, Javier (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Alvarez, Rosa (Hospital General Universitario Gregorio Marañón)
Marquina, Gloria (Hospital Universitario Clínico San Carlos (Madrid))
Diaz-Beveridge, Roberto (Hospital Universitari i Politècnic La Fe (València))
Poveda, Andrés (Instituto Valenciano de Oncologia)
Cano, Juana María (Hospital General de Ciudad Real)
Cruz-Jurado, Josefina (Hospital Universitario Canarias)
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau)
Salgado, María Angeles Vaz (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid))
Valverde-Morales, Claudia Maria. (Hospital Universitari Vall d'Hebron)
Sevilla, Isabel (Universitarios Regional y Virgen de la Victoria de Málaga)
Martínez-García, Jerónimo (Hospital Universitario Virgen de la Arrixaca (Múrcia))
Rubio-Casadevall, Jordi (Institut Català d'Oncologia)
de Juan Ferre, Ana (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
Carrasco, Juan Antonio (Hospital Álvaro Cunqueiro (Vigo))
Moura, David S. (Instituto de Biomedicina de Sevilla)
Gurruchaga-Sotes, Ibon (Hospital Universitario Miguel Servet (Saragossa))
Gutiérrez, Antonio (Hospital Universitari Son Espases (Palma de Mallorca, Balears))

Date:	2021
Abstract:	The aim of this study was to identify an easily reliable prognostic score that selects the subset of advanced soft tissue sarcoma (ASTS) patients with a higher benefit with trabectedin in terms of time to progression and overall survival. A retrospective series of 357 patients with ASTS treated with trabectedin as second-or further-line in 19 centers across Spain was analyzed. First, it was confirmed that patients with high growth modulation index (GMI > 1. 33) were associated with the better clinical outcome. Univariate and multivariate analyses were performed to identify factors associated with a GMI > 1. 33. Thus, GEISTRA score was based on metastasis free-interval (MFI ≤ 9. 7 months), Karnofsky < 80%, Non L-sarcomas and better response in the previous systemic line. The median GMI was 0. 82 (0-69), with 198 patients (55%) with a GMI < 1, 41 (11. 5%) with a GMI 1-1. 33 and 118 (33. 1%) with a GMI > 1. 33. The lowest GEISTRA score showed a median of time-to-progression (TTP) and overall survival (OS) of 5. 7 and 19. 5 months, respectively, whereas it was 1. 8 and 3. 1 months for TTP and OS, respectively, for the GEISTRA 4 score. This prognostic tool can contribute to better selecting candidates for trabectedin treatment in ASTS.
Note:	Altres ajuts: PharmaMar S.A.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Trabectedin ; Sarcoma ; Growth modulation index ; Prognostic score ; L-sarcoma ; GEISTRA
Published in:	Cancers, Vol. 13 Núm. 4 (february 2021) , p. 1-15, ISSN 2072-6694

DOI: 10.3390/cancers13040792
PMID: 33672857

15 p, 942.2 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles